论文部分内容阅读
目的:观察艾塞那肽联合二甲双胍治疗2型糖尿病的有效性及安全性。方法:将肥胖型2型糖尿病80例随机分为实验组和对照组。实验组给予艾塞那肽联合二甲双胍治疗,对照组给予二甲双胍治疗。观察2组患者治疗第0月、第1月、第2月、第3月时FBG、2hBG、HbA1c、BMI、TC、TG和LDL水平。检测3个月治疗结束时两组患者的C肽水平,并进行比较。结果:2组患者治疗3个月后,FBG、2hBG、HbA1c和BMI均显著下降,与治疗前相比差异具有显著性(P<0.05)。同时实验组较对照组显著下降(P<0.05)。对照组的TC、TG和LDL较治疗前降低,但差异无显著性(P>0.05)。而实验组较治疗前显著降低(P<0.05),同时较对照组显著下降(P<0.05)。治疗3个月后,实验组的C肽水平显著高于对照组(P<0.05)。结论:肥胖型2型糖尿病应用艾塞那肽联合二甲双胍可获得良好的血糖、体质量和血脂控制,同时可改善胰岛功能,不增加低血糖发生,安全有效。
Objective: To observe the efficacy and safety of exenatide and metformin in the treatment of type 2 diabetes mellitus. Methods: 80 obese type 2 diabetic patients were randomly divided into experimental group and control group. Experimental group given exenatide combined with metformin treatment, the control group was treated with metformin. The levels of FBG, 2hBG, HbA1c, BMI, TC, TG and LDL were observed in two groups at 0, 1, 2 and 3 months after treatment. C-peptide levels were measured in both groups at the end of the 3-month treatment period and compared. Results: FBG, 2hBG, HbA1c and BMI decreased significantly in both groups after 3 months of treatment, with significant difference compared with those before treatment (P <0.05). At the same time experimental group than the control group decreased significantly (P <0.05). TC, TG and LDL in control group were lower than those before treatment, but there was no significant difference (P> 0.05). The experimental group was significantly lower than before treatment (P <0.05), while significantly decreased compared with the control group (P <0.05). Three months after treatment, the level of C peptide in the experimental group was significantly higher than that in the control group (P <0.05). Conclusion: Exenatide combined with metformin in obese type 2 diabetes patients can achieve good blood glucose, body weight and lipid control, meanwhile, it can improve islet function without increasing hypoglycemia and is safe and effective.